Handok is taking a break from its pursuit of reimbursement for ‘Pivlaz,’ a new drug used to prevent cerebral vasospasm in patients with subarachnoid hemorrhage that the company is supplying and distributing in Korea.

The company immediately applied for Pivlaz’s reimbursement to the Health Insurance Review and Assessment Service after receiving approval in December last year, but was found to have voluntarily withdrawn the application recently. The company is expected to realign its strategy and then pursue reimbursement again.

According to industry sources on the 10th, Handok submitted a letter requesting the withdrawal of the application for the drug determination (reimbursem